Mechanisms of metabolic dysfunction in cancer-associated cachexia

Michele Petruzzelli¹ and Erwin F. Wagner²

¹Department of Oncology, The Medical Research Council Cancer Unit, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, United Kingdom; ²Genes, Development, and Disease Group, Cancer Cell Biology Programme, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain

Metabolic dysfunction contributes to the clinical deterioration observed in advanced cancer patients and is characterized by weight loss, skeletal muscle wasting, and atrophy of the adipose tissue. This systemic syndrome, termed cancer-associated cachexia (CAC), is a major cause of morbidity and mortality. While once attributed solely to decreased food intake, the present description of cancer cachexia is a disorder of multiorgan energy imbalance. Here we review the molecules and pathways responsible for metabolic dysfunction in CAC and the ideas that led to the current understanding.

Human cancers develop as a localized focus of uncontrolled cell growth and subsequently progress to a systemic disease (Fig. 1). Cancer research primarily focuses on the agents, events, and genetic alterations underlying tumor initiation, progression, and metastasis. However, the vast majority of end-stage cancer patients suffer a systemic illness defined as cachexia, a widespread but poorly understood condition [Lok 2015]. The “most time honored symptom of cancer” [Editors 1929], cachexia is the prototype image that comes to mind when thinking of cancer. The loss of appetite, energy, and vigor; the languid and unsmiling face; the sallow and anemic aspect; and the skinny and wasted complexion are all too familiar to physicians treating cancer patients. Despite the obvious clinical picture, a formal definition of the diagnostic criteria has only recently been reached [Fearon et al. 2011]. The current consensus for diagnosis is the unintentional loss of total body weight or skeletal muscle mass. Importantly, cancer-associated cachexia (CAC) is a complex metabolic disorder with profound changes in energy balance, which might be already irreversible at the time of obvious body weight loss. While cachexia itself is often rapidly progressive, marking the irreversible decline in health and survival, the time when cachexia appears in the clinical history of the cancer patients is, at present, mostly unpredictable. The severity of CAC is often unrelated to tumor size or stage, with small tumors commonly leading to severe wasting, as is the case, for example, for pancreatic and lung tumors. In contrast, widely disseminated cancers may cause death without any evidence of CAC. The reasons for this paradoxical lack of correlation between tumor burden and the degree of cancer cachexia are, at present, elusive. Furthermore, CAC often results in fewer completed cycles of chemotherapy with higher complication rates. Therefore, a better characterization of the metabolic changes in the organism affected by cancer is urgently needed in order to recognize the early events of CAC and improve its prognosis. In this review, we discuss the conceptual advances that shaped the current understanding of the systemic metabolic maladaptation to cancer.

Research milestones in cancer cachexia

For centuries, the concept that a local malignant growth could be responsible for systemic effects has been under debate [E.F.B. 1909]. Rather than a specific disease, the wasting associated with cancer was attributed to nonspecific pathological complications of the tumor, such as anorexia, hemorrhage, infection, or ulceration of the neoplastic tissue [Willis 1948]. In contrast, those in favor of systemic alterations produced by the tumor on the host considered cachexia the result of either direct secretion by the tumor of some substances active in distant organs or uptake by the tumor of components from the blood that are essential for the correct functioning of distant organs [Greenstein 1947; Donovan 1954]. Evidence supporting one hypothesis or the other was slim, and the contention was disputed on the basis of small clinical case series and anecdotal post-mortem findings [Donovan 1954].

During the past decades, a vast body of investigation has reshaped our understanding of CAC [Fig. 2]. Experimental work with animal models of cancer rather than...
transformed cell to a systemic disease. At the matic representation of the evolution of cancer from a single

**Figure 1.** Multilevel cancer pathophysiology at a glance. Schematic representation of the evolution of cancer from a single transformed cell to a systemic disease. At the “cell” level, the transformed cell (purple) is characterized by the presence of genome instability and mutations, sustained proliferative signaling, avoidance of growth suppressors, replicative immortality, resistance to cell death, and deregulated cellular energetics. At the “tissue” level, the proliferation of the tumor mass is associated with induction of angiogenesis, activation of invasion, promotion of inflammation, and avoidance of immune destruction—all hallmarks of cancer as described in Hanahan and Weinberg (2011). At the “organism” level, the developing cancer induces changes in distant organs, including metastasis, metabolic failure, and cancer cachexia, which is not included in the hallmarks of cancer. Cancer cells are shown in purple, “normal” cells are indicated in blue, immune cells are shown in green, and blood vessels are indicated in red. The arrow at the “cell” level points to the conversion from a normal cell to a cancer cell, whereas the arrow pointing to the “organism” depicts a growing tumor (purple).

observations in the clinical setting led to the recognition of CAC as a legitimate entity independent of the effects of anorexia or mechanical interference of the tumor with the surrounding tissues. When tumor-bearing rats were force-fed a high-fat diet, weight loss was prevented. However, the development of anemia and the enlargement of the adrenal glands were not affected, thus showing the existence of systemic manifestations of cancer independent of nutritional intake (Begg and Dickinson 1951). Following the kinetics of tissue loss in tumor-bearing mice, it was noticed that adipose tissue wasting was an early event, occurring at a time when the tumor was barely palpable (Costa and Holland 1962). Surprisingly, fat loss could also be induced by nonviable tumor preparations, indicating that soluble components of tumor extracts can induce cancer cachexia (Costa and Holland 1962). The causes for the systemic effects associated with cancer were more sophisticated than just reduced food intake and needed to be sought in the complex relationship between the host and the tumor. Analogies between systemic responses to infectious agents and cancers were noted, including fever, leukocytosis, and increased serum levels of acute phase response proteins (Rosenthal and Franklin 1975). The first evidence that inflammatory mediators—namely, cytokines—were involved in the process of protein breakdown in isolated skeletal muscle and a potential role for interleukin-1 [IL-1] in muscle degradation during fever was published in 1983 (Baracos et al. 1983). Particular attention was received by the somewhat paradoxical increase in serum lipid levels despite the obvious loss of body weight in severely sick patients. It was found that such hypertriglyceridemia could be induced experimentally in animals by either injection of infective agents or transplantation of tumors (Rouzer and Cerami 1980, Kawakami and Cerami 1981). Hypertriglyceridemia was the result of lipoprotein lipase (LPL) inhibition and could be reproduced by injecting animals with conditioned medium from inflammatory cells incubated with endotoxin (Kawakami and Cerami 1981).

In 1985, Bruce Beutler in Anthony Cerami’s group (Cerami et al. 1985) provided definitive proof that circulating mediators could cause cachexia, showing that culture medium from endotoxin-activated macrophages caused body weight loss when injected into mice. The molecule in the conditioned medium causing cachexia was purified and termed “cachectin” (Beutler et al. 1985). Subsequent determination of the complete primary structure of cachectin revealed its identity with tumor necrosis factor-α [TNFα] (Fransen et al. 1985; Pennica et al. 1985). It should be noticed that these early preparations of conditioned medium contained multiple macrophage products, and it is therefore erroneous to attribute all of the cachexigenic action to the effect of TNFα alone. Furthermore, TNFα causes systemic shock and the release of other cytokines, further confounding the attribution of the observed phenotype to a single identifiable factor. However, despite the technical limitations, these early studies contributed to a conceptual evolution in the field of cachexia research, and the wasting syndrome was finally regarded as the result of the host response to the tumor. Clinical evidence confirmed the conclusions of preclinical investigations showing that intravenous hyperalimentation could not alleviate cachexia in cancer patients (Evans et al. 1985). Remarkably, the focus of research had gradually shifted from the nature of the invasive agent (infection or cancer) to the quality of the response elicited in the organism. The immune system was the likely source of all mediators responsible for the systemic changes, and a variety of cytokines joined TNFα in the ability to cause systemic alterations (Beutler and Cerami 1986). However, despite the clear role played by cytokines in experimental cachexia, their involvement in human disease was less obvious, and clinical translation yielded ambiguous results (Balkwill et al. 1987; Socher et al. 1988). Perhaps as a consequence of the disappointment generated by the lack of clinical benefits from basic findings, the pace of research in the field of cancer cachexia progressively reduced. An additional explanation could be the rapid progress of molecular biology of cancer in the mid-1980s. That was the time when the first oncogenes were discovered, and the simplistic view of reducing cancer to a single base mutation was occupying the entire scene (Weinberg 2014). The war on cancer
seemed to be close to a favorable ending, and the focus of research zoomed back to the tumor itself rather than the response that the tumor ignites in the organism.

Cancer cachexia is an energy balance disorder linked to inflammation

Weight loss is a cardinal sign of cachexia and represents the main independent predictor of mortality in cancer patients [Fearon et al. 2012]. The mechanisms for weight loss in cancer are multiple, including decreased nutrient intake, systemic metabolic dysfunction, and increased energy expenditure. Inflammation represents a common denominator in the pathophysiology of energy imbalance during cachexia. In mice, the peritoneal injection of cancer cells expressing TNFα has been shown to cause weight loss and cachexia. In contrast, mice injected with the same cells without TNFα do not lose body weight [Oliff et al. 1987]. Similar results have been obtained with IL-6 in preclinical models [Strassmann et al. 1992]. Both host- and tumor-derived cytokines cooperate in a complex way with the tumor microenvironment to sustain tumor growth and cachexia [Cahlin et al. 2000]. In support of a role of cancer-derived cytokines, it has been shown recently that expression of the cytokine TNF-related weak inducer of apoptosis [TWEAK] by cancer cells causes cachexia, and the effect is similar in wild-type and TWEAK-deficient mice [Johnston et al. 2015].

As the cancer persists, it is assumed that ongoing local inflammation may reach a threshold when cytokines spill into the circulation, thus transforming the cancer disease from a localized tumor to a systemic impairment. Unfortunately, such a simplistic view does not stand present experimental validation. The levels of serum cytokines do not correlate with the appearance of cachexia in cancer patients [Fearon et al. 2012]. Furthermore, treatments with antibodies targeting a single cytokine have failed so far to prevent or significantly ameliorate the wasting syndrome [Penna et al. 2010; Fearon et al. 2013]. Very recent data emphasize the multifactorial etiology of CAC, showing now that a combination of cytokines and/or additional mediators is responsible for the cachectic phenotype [Schaefer et al. 2016].

Despite the absence of a simplistic threshold model linking cytokine levels to cachexia development, a rich body of evidence supports their causal role in the metabolic dysfunction observed in CAC. Mechanistically, cytokines were shown to increase the metabolic rate through activation of thermogenesis, inhibit adipocyte and skeletal myocyte differentiation, and reduce food intake [Guttridge et al. 2000; Li et al. 2002; Ruan et al. 2002; Arruda et al. 2010]. However, weight loss in cancer patients cannot be attributed solely to decreased food intake, since dietary supplements fail to reverse cachexia [Bruera and Sweeney 2002]. In contrast, a recent study in mice expressing high levels of the proinflammatory cytokine IL-18 suggests that high caloric feeding in the context of metabolic dysfunction may exacerbate weight loss and cause fatal cachexia [Murphy et al. 2016]. In the context of cancer, metabolic dysfunction is caused by deregulated carbohydrate and lipid metabolism.

Altered carbohydrate metabolism in cancer cachexia

Carbohydrate intolerance in cancer patients has long been noted [Rohdenburg et al. 1919]. While fasting blood sugar concentration between control and cancer groups did not differ significantly, intravenous glucose tolerance tests showed significantly decreased disappearance of glucose in cancer patients [Bishop and Marks 1959]. In the first half of the last century, Cori and Cori [1925] compared glucose levels in the venous blood from the tumor-bearing arm and the unaffected arm of a patient with a sarcoma on the forearm. Glucose levels from the tumor-bearing arm were reduced, thus confirming in vivo the increased rate of tumor glycolysis [Cori and Cori 1925]. Since tumor tissue takes up glucose, the decreased disappearance of glucose observed in the tolerance test must be sought in metabolic alterations in the host tissues associated with cancer development. Either increased hepatic glucose production or a decrease in peripheral utilization could account for the reduced glucose tolerance observed in cancer patients. Despite decreased hepatic glycogen stores, endogenous glucose production is increased in cachectic patients due to increased hepatic glucose recycling via lactate, a phenomenon termed the Cori cycle.
(Holroyde et al. 1984). Apart from these studies, clinical investigations on glucose metabolism in cachectic patients are noticeably thin. While one study suggests that glucose intolerance may worsen with the development of cachexia [Jasani et al. 1978], other studies found that glucose intolerance did not correlate with body weight loss [Yoshikawa et al. 2001; Agustsson et al. 2011]. Very recently, elegant genetic studies in the fruit fly *Drosophila* have identified an important role of insulin signaling in inducing a cachexia-like systemic wasting following transplantation of *Drosophila* tumors [Figuerola-Clarevega and Bilder 2015; Kwon et al. 2015]. Both studies have identified a tumor-secreted factor, *Inspl2/IGFBP* [an insulin-binding protein and antagonist of insulin/insulin-like growth factor [IGF] signaling], that is responsible for the wasting phenotypes in organs distant from the transplanted tumors [Wagner and Petruzzelli 2015].

### Role of lipids, burning fat, and white adipose tissue (WAT) browning

Besides changes in carbohydrate metabolism, the handling of lipids between tissues is severely impaired in cancer patients. The deposition of triglycerides [TGs] in cytoplasmic lipid droplets represents the most efficient form to store lipids in WAT and many other cell types. Already in 1848, the French physiologist Claude Bernard discovered that TGs, commonly called fat, are digested in the gut before they can be absorbed. The hydrolysis of TGs, designated lipolysis, generates glycerol and fatty acids [FAs]. The enzymes mediating intracellular lipolysis include adipose TG lipase (ATGL) and the hormone-sensitive lipase [HSL], while LPL is responsible for the hydrolysis of plasma TGs of lipoproteins in the vascular system [Young and Zechner 2013]. FA uptake and TG synthesis decline in WAT in murine cancer models, whereas, in human CAC, it is associated with normal lipid synthesis but elevated lipolysis in WAT. This suggests that lipid catabolism is more relevant than inhibition of lipid synthesis for the loss of WAT in CAC [Dahlman et al. 2010]. These findings were corroborated in an elegant study demonstrating that WAT lipolysis in cancer patients is increased due to elevated enzyme activities of ATGL and HSL [Das et al. 2011]. Importantly, genetic deletion of *Atgl* in mice prevented increased lipolysis and the reduction of WAT and skeletal muscle mass in certain models of CAC. Similar results were also observed, although to a lesser extent, when HSL was inactivated [Das et al. 2011]. Lipolysis in CAC is induced by many serum factors secreted by tumor or host cells, including hormones such as glucocorticoids and catecholamines, cytokines like TNFa, IL-1β, IL-6, prostaglandins; and a zinc–glycoprotein, ZAG, also called lipid-mobilizing factor [Tisdale 2010]. How functional lipolysis impacts the development of cancer cachexia is the focus of ongoing investigations in several laboratories (for review, see Tsoli et al. 2015).

While quantitative changes in WAT content during cancer cachexia have long been recognized, only recently a qualitative change in the morphology and function of white adipocytes has been described. During the progression of cancer cachexia in preclinical models, WAT cells gradually convert to brown adipose tissue (BAT)-like cells, also called “beige” cells, in a process termed “browning” [Kir et al. 2014; Petruzzelli et al. 2014]. Beige cells are characterized by high mitochondrial content and increased expression of uncoupling protein 1 (UCP1), which is responsible for uncoupling the use of mitochondrial electron transport from ATP synthesis to thermogenesis [Nedergaard and Cannon 2014]. The phenomenon of browning was initially described as an adaptive response to prolonged exposure to cold environments [Cousin et al. 1992]. When exposed to cold temperatures, mice deficient in the ability to activate thermogenesis rapidly lose core body temperature and are more susceptible to cold-induced damage [Nguyen et al. 2011]. The induction of browning in humans was initially hypothesized on the basis of increased fluorodeoxyglucose (FDG) uptake in WAT depots using positron emission tomography (PET) [Nedergaard et al. 2007] and later confirmed at the histological level [Cypess et al. 2009; van Marken Lichtenbelt et al. 2009; Virtanen et al. 2009]. Recent investigations have shown that the role of browning is not limited to cold acclimatization. In preclinical models of diet-induced obesity, browning promotes systemic energy expenditure, which results in body weight loss and improved insulin sensitivity. The protection conferred by browning against high-fat diet-induced obesity suggests pharmacological enhancement of browning as a promising therapeutic strategy for metabolic disorders due to excess of nutrients [Feldmann et al. 2009; Yoneshio et al. 2013]. While the effect of browning is identical in both obesity and cancer, the metabolic result is the opposite. Increased lipid mobilization and energy expenditure are favorable in obesity while being deleterious in cancer (Fig. 3). In fact, different from obesity and the metabolic syndrome, browning in the context of cancer exacerbates the metabolic dysfunction, enhancing energy dissipation and contributing to the progression of CAC [Kir et al. 2014; Petruzzelli et al. 2014]. Browning in cancer-bearing mice is a systemic event manifested in multiple WAT depots. It precedes the onset of skeletal muscle atrophy and determines a hypermetabolic state characterized by high resting energy expenditure. Notably, browning is not restricted to one experimental model and is not associated with one specific cancer type, since it was documented in complementary model systems, including genetically engineered mouse models (GEMMs), carcinogen-induced cancers, syngeneic transplants of murine cancer cells, and xenogeneic transplants of human cancer tissue [Petruzzelli et al. 2014]. Recently, browning of WAT has been shown to take part in the pathogenesis of hypermetabolism commonly observed in other morbid conditions, like post-burn injury, severe adrenergic stress, and kidney failure [Kir et al. 2015; Patsouris et al. 2015; Sidossis et al. 2015]. Treatment of mice with a synthetic thyroid hormone receptor agonist induces adaptive thermogenesis in subcutaneous WAT, thus suggesting a role for WAT browning also in hyperthyroidism [Lin et al. 2015].
Cancer cachexia and metabolic dysfunction

Figure 3. Mechanisms and consequences of WAT browning in cancer cachexia. At the “cell” level, beige adipocytes are induced in WAT by a combination of signaling pathways, including β-adrenergic stimulation, inflammation mediated by IL-6, and the presence of parathyroid-related peptide (PTHrP). As a result, UCP1 levels and mitochondrial content are increased. At the “tissue” level, CAC is associated with the appearance of islets of beige adipocytes in WAT, surrounded by white adipocytes of reduced size due to ongoing lipolysis. WAT browning and lipolysis result in decreased energy storage and increased production of heat. In the context of obesity, WAT browning is beneficial, while in cancer patients, it is detrimental.

Tumors can directly activate thermogenesis in beige cells through the secretion of parathyroid-related peptide (PTHrP), which has been identified in the supernatants from a murine lung carcinoma cell line and shown to drastically induce the expression of UCP1 (Kir et al. 2014). At the molecular level, transformation of white adipocytes into beige adipocytes requires the function of the transcriptional coregulator PRDM16. Interestingly, fat-specific Prdm16-deficient mice challenged in a model of cancer cachexia showed a significant reduction of browning, thermogenic activity, and WAT atrophy. Importantly, injection of cachectic xenotransplant mice with a neutralizing antibody specific for PTHrP was beneficial, reducing the intensity of cancer cachexia and skeletal muscle atrophy. In lung and colorectal cancer patients, higher plasma PTHrP concentrations are associated with increased energy expenditure and enhanced lean tissue wasting, thus confirming the therapeutic potential of inhibiting PTHrP in human cancer (Kir et al. 2014). While treatment of cachectic mice with a PTHrP antibody ameliorated the severity of cachexia, it did not inhibit it completely, thus suggesting that other tumor-derived or host-derived molecules collaborate with PTHrP in the induction of browning and systemic wasting.

Next to direct activation of browning through tumor-derived PTHrP, systemic inflammation and activation of the β-adrenergic pathway represent complementary mechanisms involved in the pathogenesis of browning during CAC (Petruzzelli et al. 2014). Plasma levels of IL-6 are increased in cachectic mice, and genetic blockade of IL-6 by stable incorporation of a shRNA led to a drastic reduction of the severity of cancer cachexia in a xenogeneic cancer model. In addition, IL-6 receptor (IL-6-R) knock-out mice implanted with melanoma cells displayed reduced browning when compared with control mice, further corroborating the role of IL-6 in the activation of the thermogenic program in white adipocytes (Petruzzelli et al. 2014). While the direct induction of UCP1 expression by incubation of adipocytes in the presence of recombinant IL-6 is modest, indirect mechanisms are likely to enhance IL-6-induced browning, such as alternative activation of macrophages (Mauer et al. 2014). These cells have been shown to sustain adaptive thermogenesis by means of enhanced recruitment of β-adrenergic fibers (Nguyen et al. 2011). Indeed, macrophages infiltrate the WAT of cachectic mice and express markers of alternative activation. The link between the immune system and adipose tissue biology is further supported by recent investigations showing WAT browning following microbiota depletion (Suarez-Zamorano et al. 2015; Yeoh and Vijay-Kumar 2015). Interestingly, colonization of the intestine by different strains of bacteria has been shown to modulate disease severity and cachexia development in mouse models (Schieber et al. 2015). A role for therapeutic agents targeting intestinal function in CAC remains largely speculative at present (Klein et al. 2013). Whether inhibition of browning may indirectly affect tumor metabolism is not known. Systemic alterations of the metabolism in the host are predicted to affect local metabolic pathways of cancer cells, although more experimental data are needed.

In addition to browning, many studies using murine cancer models have demonstrated that lipolysis induces the activation of interscapular BAT during cancer cachexia, further contributing to energy uncoupling in mitochondria with the subsequent worsening of the negative energy balance (Tsoli and Robertson 2012). BAT has a key role in thermogenesis and energy balance and therefore may well participate in energy expenditure in cancer patients. BAT has been shown to be present in adult humans, and a role for BAT in CAC is possible but is by no means definitively proven (Bauwens et al. 2014).

Muscle wasting in cancer cachexia

CAC is characterized by muscle atrophy, which severely impairs the patient’s mobility because of fatigue and weakness (Cohen et al. 2015). Early labeling experiments have shown that different mechanisms cause skeletal muscle atrophy in different conditions. Increased myofibrillar degradation was observed in skeletal muscle
atrophy caused by denervation, while a combination of decreased synthesis and increased degradation was responsible for cortisone-induced muscle atrophy (Goldberg and Goodman 1969). In animal models, glucocorticoids did not cause skeletal muscle atrophy at physiological concentrations but only at increased concentrations under pathological conditions (Tomas et al. 1979). Therefore, increased adrenal activity and glucocorticoid levels in cancer patients were hypothesized as likely to be responsible for skeletal muscle-wasting during cancer cachexia. However, adrenalectomy did not prevent skeletal muscle atrophy in tumor-bearing animals, thus arguing against a role for adrenal hyperfunction in muscle atrophy during experimental CAC (Svaninger et al. 1987). Conversely, microscopic examination of skeletal muscle from cancer cachexia patients did not show evidence of degeneration of muscular or intramuscular nerve bundles, thus excluding also a role for denervation (Marin and Denny-Brown 1962). The factors responsible for skeletal muscle atrophy in CAC remained elusive until the important role of cytokines was finally identified.

Administration of TNFα or IL-1 in mice was found to cause loss of skeletal muscle mass similar to what was observed in cachectic cancer patients (Fong et al. 1989). However, while treatment of tumor-bearing rats with anti-cytokine immunoglobulins reduced skeletal muscle atrophy, the protection against systemic wasting was only partial (Costelli et al. 1993). Evidence accumulated pointing to the idea that, in cachexia, the synergistic action of multiple cytokines and other mediators was responsible for skeletal muscle atrophy and likely most of the other components of the wasting syndrome (Argiles and Lopez-Soriano 1999). At the molecular level, the ubiquitin-dependent proteasome pathway (UPP) was identified as one important mechanism underlying muscle breakdown in pathologic states, such as prolonged fasting and metabolic acidosis (Wing and Goldberg 1993; Mitch et al. 1994). Similarly, activation of the UPP was observed in preclinical models of cancer cachexia (Temparasis et al. 1994; Baracos et al. 1995). At the genetic level, deletion of muscle-specific E3 ligases Atrogin-1/MAFbx or Murf1 (muscle RING finger protein 1) protected skeletal muscle against experimental atrophy (Bodine et al. 2001). In contrast, muscle-specific activation of Nf-κB caused skeletal muscle wasting (Cai et al. 2004). In vitro studies have shown a role for TNFα in the activation of NF-κB, which results in inhibition of myocyte differentiation (Guttridge et al. 2000). In addition, cytokines cause a reduction in myofibrillar protein by decreasing the expression of nuclear transcription factor MyoD and through activation of UPP (Acharya et al. 2004). A large body of evidence implicates the FOXO family of transcription factors as key mediators of skeletal muscle atrophy during CAC as well as during fasting and other pathological conditions (Egerman and Glass 2014; Cohen et al. 2015). The catabolic effects of FOXO transcription factors are mediated by induction of the atrophy-related ubiquitin ligase Atrogin-1/MAFbx (Sandri et al. 2004) and Murf1 (Zhao et al. 2007; Cohen et al. 2009). A third E3 ligase, Mul1, has been shown to be involved in the reduction of oxidative capacity in cachectic muscles by controlling mitochondrial protein degradation (Lokireddy et al. 2012).

Compelling evidence shows that the atrophy-related genes, also called atrogenes, are directly responsible for skeletal muscle atrophy due to conditions different from CAC, such as denervation, diabetes, or renal failure. Therefore, this points to a concept that a common transcriptional program underlies the loss of skeletal muscle mass independently of the triggering factor (Lecker et al. 2004; Sandri et al. 2006). Skeletal muscle activation of atrogenes in experimental cachexia may also be the result of cross-talk mechanisms between distant organs. As previously noticed, genetic inhibition of lipolysis ameliorates skeletal muscle atrophy in mouse models of CAC (Das et al. 2011). Lipolysis determines an elevated flux of FAs from adipose tissue, and increased FA uptake in the skeletal muscle leads to ceramide synthesis, reduced mTOR activity, and Atrogin and Murf expression (Corcoran et al. 2007; De Larichaudy et al. 2012). In this regard, intramyocellular lipid droplets have been described in skeletal muscle of cancer patients, and its overall content was associated with the extent of body weight loss (Stephens et al. 2011).

While there is considerable experimental evidence for the contribution of atrophy-related UPP in preclinical models, its direct role in human disease and human CAC in particular is, at present, controversial. Conflicting evidence comes from studies that have measured the expression levels of different UPP components in cancer cachexia patients. Arguing against a direct role, individual components of the UPP were actually found to be unchanged or even down-regulated in cancer patients with suppression of both anabolic and catabolic processes, indicative of reduced muscle turnover that was restored to normal levels following tumor resection (Stephens et al. 2010; Gallagher et al. 2012). On the contrary, different studies reported an increase in the expression levels of proteasome subunits in skeletal muscle of cancer patients with weight loss (Williams et al. 1999; Khal et al. 2005). Besides overexpression of the ubiquitin gene, direct measurement of the proteasome proteolytic activity showed enhancement in skeletal muscles of patients with gastric cancer when compared with noncancer surgical controls and was associated with advanced tumor stage and poor nutritional status (Bossola et al. 2003). These conflicting data comparing animal models and patients with CAC may be due to differences in timing of examination of the skeletal muscle. The analysis in rodents was performed during or at the end of rapid skeletal muscle wasting, while, in cachectic humans, it was performed in the final stage that follows the period of dramatic wasting. It has been shown that changes in expression levels of atrogenes are maximal during the periods of rapid changes in skeletal muscle mass, while further weight loss is associated with reduced gene expression (Khal et al. 2005). Multiple time points during skeletal muscle atrophy in human cachexia must be measured before conclusions can be drawn. Additional mechanisms of muscle atrophy in cachexia have been suggested, including activation of the JAK/STAT3 pathway (Bonetto et al. 2012, Shum and
Polly 2012], induction of apoptosis [He et al. 2014], mitochondrial dysfunction [White et al. 2011], and the direct effect of cancer chemotherapy [Le Bricon et al. 1995].

Besides the factors responsible for skeletal muscle atrophy, studies on factors relevant for muscle hypertrophy have also provided important insights into the mechanisms underlying muscle wasting in CAC. Insulin is the main anabolic factor opposing the catabolic effects of glucocorticoids, and the absence of insulin in rats contributes to skeletal muscle atrophy [Price et al. 1996]. At the molecular level, IGF-1 activates insulin receptor substrate 1, which signals through PI3K–AKT to induce protein synthesis by activating mTOR [Rommel et al. 2001]. Skeletal muscle hypertrophy is also observed in the presence of inactivating mutations in Myostatin (Schuelke et al. 2004), while forced expression of Myostatin causes muscle atrophy in adult mice [Zimmers et al. 2002]. The muscle hypertrophy observed in myostatin-deficient mice is abolished after inhibition of bone morphogenetic protein (BMP) signaling, which results in up-regulation of the muscle ubiquitin ligase of the SCF complex in atrophy-1 [MUSA1] [Sartori et al. 2013]. Myostatin and Activin are members of the transforming growth factor β (TGFβ) family that were shown to be involved in skeletal muscle atrophy by binding to the Myostatin/Activin type II receptor B (ActRIIB) [Benny Klimek et al. 2010]. Interestingly, expression of a dominant-negative ActRIIB in transgenic mice results in skeletal muscle hypertrophy [Lee and McPherron 2001]. Furthermore, expression of Myostatin is increased upon inflammatory signaling, whereas it inhibits myoblast differentiation and increases Foxo activation and the expression of ubiquitin ligases [Sartori et al. 2009; Trendelenburg et al. 2009]. A recently identified PGC1α isoform, Pgc1α4, has been shown to be highly expressed in exercised muscle and was able to prevent skeletal muscle atrophy by repressing Myostatin activity. Notably, mice with skeletal muscle expression of Pgc1α4 were protected from CAC [Ruas et al. 2012]. As an additional mechanism for skeletal muscle dysfunction in cancer, TGFβ release from bone metastasis has been demonstrated to lower intracellular calcium signaling and reduce the force of muscle contraction [Waning et al. 2015].

From a therapeutic perspective, recent clinical trials have provided proof of principle that it is possible to promote skeletal muscle anabolism in cancer patients. A high-protein diet supplemented with leucine has been shown to increase muscle fractional synthetic rate in a small randomized trial in cancer patients [Deutz et al. 2011]. However, it has been reported that leucine supplementation increases pancreatic cancer growth in mice, a mechanism mediated by activation of mTOR [Liu et al. 2014]. The landmark study by Zhou et al. [2010] has shown that pharmacological blockade of ActRIIB in mouse models of CAC ameliorates skeletal muscle atrophy and prevents atrophy of cardiac muscle. Importantly, ActRIIB blockade significantly prolonged survival even in the absence of direct effects on tumor growth and cytokine secretion. At present, it is not clear whether Myostatin inhibition may also ameliorate skeletal muscle atrophy by direct stimulation of stem cell proliferation. Protection against skeletal muscle atrophy and regrowth of skeletal muscle myocytes are observed after ActRIIB blockade, although a causative role of Myostatin inhibition has yet to be proven. Impaired regenerative capacity of myogenic cells has been recently described in CAC, a process mediated by NF-κB-dependent expression of the self-renewing factor Pax7 [He et al. 2013]. Furthermore, inhibition of ActRIIB by a humanized monoclonal antibody has been shown to increase skeletal muscle mass and prevent glucocorticoid-induced atrophy in mice [Lach-Trifielieff et al. 2014]. The beneficial effects of inhibiting the Myostatin/Activin pathway is not limited to ameliorating skeletal muscle atrophy but was also shown to improve other pathological conditions in preclinical models, such as insulin resistance and systemic inflammation. The translational potential of Myostatin/Activin antagonism is currently being evaluated in multiple clinical settings [Han et al. 2013; Cohen et al. 2015]. Implementation of these findings in clinical practice is anticipated to potentially ameliorate the prognosis of cancer patients.

The role of the liver in cancer cachexia

Next to WAT and skeletal muscle, the liver is of primary importance in the control of systemic metabolism. However, the nature and extent of liver damage during CAC has received little attention. Similarly, the contribution of the liver to the metabolic dysfunction observed in cachexia is currently poorly characterized. Enhanced liver inflammation during CAC is suggested by increased infiltration of macrophages in the livers of pancreatic cancer patients with cachexia when compared with pancreatic cancer patients without cachexia [Martignoni et al. 2009]. Activated macrophages in the liver parenchyma may provide a local source of IL-6 production, which stimulates the synthesis of hepatic acute-phase protein [Castell et al. 1989]. Preclinical investigations have shown that hepatic oxidative phosphorylation is reduced in a rat model of peritoneal carcinosis, concomitant with increased energy wasting and production of reactive oxygen species [Dumas et al. 2010]. Furthermore, clinical investigations have shown that hepatic gluconeogenesis is increased in cancer patients [Yoshikawa et al. 1999]. Last, hepatic steatosis has been documented in CAC patients [Teli et al. 1995]. At the molecular level, hepatic gene expression of the transcription factor TGFβ1-stimulated clone 22 D4 (TSC22D4) is increased in experimental cachexia and correlates with the degree of systemic wasting [Jones et al. 2013]. Gene expression levels of the nuclear receptor cofactor receptor-interacting protein 140 (RIP140) are also increased in CAC and may contribute to liver steatosis by preventing the release of TG stores [Berriel Diaz et al. 2008].

Endocrine routes to cancer cachexia

Activation of neuroendocrine responses plays a major role in CAC [Fearon et al. 2012]. The role of the hypothalamus
Cytokines and tumor/host-derived factors

Figure 4. Conceptual evolution of the understanding of cancer cachexia. The scheme depicts the way we envision multifactorial cancer cachexia in 2015, involving reciprocal compounding interactions between the tumor and the organism, which result in inflammatory and metabolic changes distant from the pathological sites of tumor growth. This way is very different from the unidirectional way that “cancer aggression” was viewed decades ago [Costa 1977].
Cancer cachexia and metabolic dysfunction

A selective set of drugs are listed: Anamorelin holds great promise, since, in two phase III clinical trials, a favorable clinical response profile was obtained in patients with cachexia-anorexia and non-small-cell lung (NSCL) cancer. Bimagrumab is under study in phase II clinical trials for sarcopenia and sporadic inclusion body myositis. Clazakizumab has been investigated in a phase II clinical trial in patients with NSCL cancer. Enobosarm has been investigated in phase II/III clinical trials in patients with muscle wasting related to cancer and is currently under investigation in phase II clinical trials in patients with breast cancer. IP-1510 has been investigated in phase II/III clinical trials in patients with advanced cancer. MABp1 is under study in a phase III clinical trial in patients with advanced colorectal cancer. REGN1033 is under study in a phase II clinical trial for sarcopenia.

Table 1. Novel pharmacological agents and potential future treatment strategies for CAC

<table>
<thead>
<tr>
<th>Agent</th>
<th>Mechanism of action</th>
<th>Physiological effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anamorelin</td>
<td>Ghrelin receptor agonist</td>
<td>Appetite-enhancing and anabolic activity</td>
<td>Garcia et al. 2015</td>
</tr>
<tr>
<td>Bimagrumab</td>
<td>Anti-ActRII monoclonal antibody</td>
<td>Prevent skeletal and anabolic activity</td>
<td>Lach-Trifilieff et al. 2014</td>
</tr>
<tr>
<td>Clazakizumab</td>
<td>Anti-IL-6 monoclonal antibody</td>
<td>Anti-inflammatory activity</td>
<td>Bayliss et al. 2011</td>
</tr>
<tr>
<td>Enobosarm</td>
<td>Selective androgen receptor modulator</td>
<td>Anabolic activity</td>
<td>Dobs et al. 2013</td>
</tr>
<tr>
<td>IP-1510</td>
<td>IL-1 receptor antagonist</td>
<td>Anti-inflammatory activity</td>
<td>Paspaliaris et al. 2011</td>
</tr>
<tr>
<td>MABp1</td>
<td>Anti-IL-1α monoclonal antibody</td>
<td>Anti-inflammatory and anti-neoplastic activity</td>
<td>Hong et al. 2014</td>
</tr>
<tr>
<td>REGN1033</td>
<td>Myostatin antagonizing antibody</td>
<td>Prevents skeletal muscle atrophy</td>
<td>Ebner et al. 2014</td>
</tr>
</tbody>
</table>

A selective set of drugs is listed: Anamorelin holds great promise, since, in two phase III clinical trials, a favorable clinical response profile was obtained in patients with cachexia-anorexia and non-small-cell lung (NSCL) cancer. Bimagrumab is under study in phase II clinical trials for sarcopenia and sporadic inclusion body myositis. Clazakizumab has been investigated in a phase II clinical trial in patients with NSCL cancer. Enobosarm has been investigated in phase II/III clinical trials in patients with muscle wasting related to cancer and is currently under investigation in phase II clinical trials in patients with breast cancer. IP-1510 has been investigated in phase II/III clinical trials in patients with advanced cancer. MABp1 is under study in a phase III clinical trial in patients with advanced colorectal cancer. REGN1033 is under study in a phase II clinical trial for sarcopenia.

will likely lead to a better understanding of the metabolic dysfunction in cancer cachexia for the benefit of cancer patients.

Acknowledgments

We are very grateful to Dr. Doug Hanahan, Dr. Anna Hupalowski, Dr. Graham Robertson, Dr. Martina Schweiger, Dr. Marta Shahbazi, Dr. Rudolf Zechner, and our laboratory colleagues. We are very grateful to Dr. Doug Hanahan, Dr. Anna Hupalowski, Dr. Martina Schweiger, Dr. Marta Shahbazi, Dr. Rudolf Zechner, and our laboratory colleagues for critical reading and comments on our manuscript. E.F. is supported by a grant from the Spanish Ministry of Economy (BFU2012-40230) and a European Research Council Advanced Grant [ERC FCK/2008/37].

References


Cancer cachexia and metabolic dysfunction from the transcriptome in sequential human muscle biopsies. _Clin Cancer Res_ 18: 2817–2827.


Cancer cachexia and metabolic dysfunction


Willis RA. 1948. Pathology of Tumors. C.V. Mosby Co., St. Louis, MO.


# Mechanisms of metabolic dysfunction in cancer-associated cachexia

Michele Petruzzelli and Erwin F. Wagner

*Genes Dev.* 2016, **30:**
Access the most recent version at doi:10.1101/gad.276733.115

<table>
<thead>
<tr>
<th>References</th>
<th>This article cites 147 articles, 35 of which can be accessed free at: <a href="http://genesdev.cshlp.org/content/30/5/489.full.html#ref-list-1">http://genesdev.cshlp.org/content/30/5/489.full.html#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Creative Commons License</td>
<td>This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <a href="http://genesdev.cshlp.org/site/misc/terms.xhtml">http://genesdev.cshlp.org/site/misc/terms.xhtml</a>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <a href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</a>.</td>
</tr>
<tr>
<td>Email Alerting Service</td>
<td>Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or <a href="http://genesdev.cshlp.org/site/misc/terms.xhtml">click here</a>.</td>
</tr>
</tbody>
</table>